tetano
Editor, Senior Moderator
Sci Transl Med
. 2022 Mar 22;eabm3410.
doi: 10.1126/scitranslmed.abm3410. Online ahead of print.
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
Alexandra Schäfer[SUP] #[/SUP][SUP] 1 [/SUP], David R Martinez[SUP] #[/SUP][SUP] 1 [/SUP], John J Won[SUP] 1 [/SUP], Rita M Meganck[SUP] 1 [/SUP], Fernando R Moreira[SUP] 1 [/SUP], Ariane J Brown[SUP] 1 [/SUP], Kendra L Gully[SUP] 1 [/SUP], Mark R Zweigart[SUP] 1 [/SUP], William S Conrad[SUP] 1 [/SUP], Samantha R May[SUP] 1 [/SUP], Stephanie Dong[SUP] 1 [/SUP], Rao Kalla[SUP] 2 [/SUP], Kwon Chun[SUP] 2 [/SUP], Venice Du Pont[SUP] 2 [/SUP], Darius Babusis[SUP] 2 [/SUP], Jennifer Tang[SUP] 2 [/SUP], Eisuke Murakami[SUP] 2 [/SUP], Raju Subramanian[SUP] 2 [/SUP], Kimberly T Barrett[SUP] 2 [/SUP], Blake J Bleier[SUP] 2 [/SUP], Roy Bannister[SUP] 2 [/SUP], Joy Y Feng[SUP] 2 [/SUP], John P Bilello[SUP] 2 [/SUP], Tomas Cihlar[SUP] 2 [/SUP], Richard L Mackman[SUP] 2 [/SUP], Stephanie A Montgomery[SUP] 3 4 [/SUP], Ralph S Baric[SUP] 1 [/SUP], Timothy P Sheahan[SUP] 1 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, underscoring the need to develop highly effective antivirals. In the setting of waning immunity from infection and vaccination, breakthrough infections are becoming increasingly common and treatment options remain limited. Additionally, the emergence of SARS-CoV-2 variants of concern, with their potential to escape neutralization by therapeutic monoclonal antibodies, emphasizes the need to develop second-generation oral antivirals targeting highly conserved viral proteins that can be rapidly deployed to outpatients. Here, we demonstrate the in vitro antiviral activity and in vivo therapeutic efficacy of GS-621763, an orally bioavailable prodrug of GS-441524, the parent nucleoside of remdesivir, which targets the highly conserved virus RNA-dependent RNA polymerase. GS-621763 exhibited antiviral activity against SARS-CoV-2 in lung cell lines and two different human primary lung cell culture systems. GS-621763 was also potently antiviral against a genetically unrelated emerging coronavirus, Middle East Respiratory Syndrome CoV (MERS-CoV). The dose-proportional pharmacokinetic profile observed after oral administration of GS-621763 translated to dose-dependent antiviral activity in mice infected with SARS-CoV-2. Therapeutic GS-621763 administration reduced viral load and lung pathology; treatment also improved pulmonary function in COVID-19 mouse model. A direct comparison of GS-621763 with molnupiravir, an oral nucleoside analog antiviral which has recently received EUA approval, proved both drugs to be similarly efficacious in mice. These data support the exploration of GS-441524 oral prodrugs for the treatment of COVID-19.
. 2022 Mar 22;eabm3410.
doi: 10.1126/scitranslmed.abm3410. Online ahead of print.
Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice
Alexandra Schäfer[SUP] #[/SUP][SUP] 1 [/SUP], David R Martinez[SUP] #[/SUP][SUP] 1 [/SUP], John J Won[SUP] 1 [/SUP], Rita M Meganck[SUP] 1 [/SUP], Fernando R Moreira[SUP] 1 [/SUP], Ariane J Brown[SUP] 1 [/SUP], Kendra L Gully[SUP] 1 [/SUP], Mark R Zweigart[SUP] 1 [/SUP], William S Conrad[SUP] 1 [/SUP], Samantha R May[SUP] 1 [/SUP], Stephanie Dong[SUP] 1 [/SUP], Rao Kalla[SUP] 2 [/SUP], Kwon Chun[SUP] 2 [/SUP], Venice Du Pont[SUP] 2 [/SUP], Darius Babusis[SUP] 2 [/SUP], Jennifer Tang[SUP] 2 [/SUP], Eisuke Murakami[SUP] 2 [/SUP], Raju Subramanian[SUP] 2 [/SUP], Kimberly T Barrett[SUP] 2 [/SUP], Blake J Bleier[SUP] 2 [/SUP], Roy Bannister[SUP] 2 [/SUP], Joy Y Feng[SUP] 2 [/SUP], John P Bilello[SUP] 2 [/SUP], Tomas Cihlar[SUP] 2 [/SUP], Richard L Mackman[SUP] 2 [/SUP], Stephanie A Montgomery[SUP] 3 4 [/SUP], Ralph S Baric[SUP] 1 [/SUP], Timothy P Sheahan[SUP] 1 [/SUP]
Affiliations
- PMID: 35315683
- DOI: 10.1126/scitranslmed.abm3410
Abstract
The coronavirus disease 2019 (COVID-19) pandemic remains uncontrolled despite the rapid rollout of safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, underscoring the need to develop highly effective antivirals. In the setting of waning immunity from infection and vaccination, breakthrough infections are becoming increasingly common and treatment options remain limited. Additionally, the emergence of SARS-CoV-2 variants of concern, with their potential to escape neutralization by therapeutic monoclonal antibodies, emphasizes the need to develop second-generation oral antivirals targeting highly conserved viral proteins that can be rapidly deployed to outpatients. Here, we demonstrate the in vitro antiviral activity and in vivo therapeutic efficacy of GS-621763, an orally bioavailable prodrug of GS-441524, the parent nucleoside of remdesivir, which targets the highly conserved virus RNA-dependent RNA polymerase. GS-621763 exhibited antiviral activity against SARS-CoV-2 in lung cell lines and two different human primary lung cell culture systems. GS-621763 was also potently antiviral against a genetically unrelated emerging coronavirus, Middle East Respiratory Syndrome CoV (MERS-CoV). The dose-proportional pharmacokinetic profile observed after oral administration of GS-621763 translated to dose-dependent antiviral activity in mice infected with SARS-CoV-2. Therapeutic GS-621763 administration reduced viral load and lung pathology; treatment also improved pulmonary function in COVID-19 mouse model. A direct comparison of GS-621763 with molnupiravir, an oral nucleoside analog antiviral which has recently received EUA approval, proved both drugs to be similarly efficacious in mice. These data support the exploration of GS-441524 oral prodrugs for the treatment of COVID-19.